Research Article

Correlation between Serum IL-35 Levels and Bone Loss in Postmenopausal Women with Rheumatoid Arthritis

Table 2

Multivariate linear regression analysis of BMD.

CovariatesBMD
Lumbar spine (L1-L4)Total hip
OR95% CI valueOR95% CI value

Disease characteristics
 Disease duration0.010-0.036-0.0380.0960.015-0.033-0.0350.095
 ESR-0.037-0.002-0.0020.075-0.063-0.001-0.0020.063
 CRP-0.113-0.002-0.0010.315-0.114-0.002-0.0010.339
 DAS28-ESR-0.258-0.070-0.0120.086-0.301-0.067-0.0080.122
 RF-0.162-0.007-0.0040.065-0.037-0.005-0.00050.092
 ACPA-0.2500.000-0.0000.089-0.3000.000-0.0000.097
BTMs
β-CTX-0.1650.000-0.0000.021-0.0750.000-0.0000.050
 ALP0.063-0.003-0.0020.0590.032-0.002-0.0020.079
25-(OH) VitD30.134-0.003-0.0130.0820.032-0.003-0.0110.093
IL-350.463-0.009-0.0330.0260.254-0.014-0.0250.025
Medications
 HCQ0.156-0.157-0.0300.1810.065-0.109-0.0630.596
 MTX0.027-0.101-0.1260.8250.026-0.093-0.1150.836
 LEF0.075-0.090-0.1640.5630.126-0.062-0.1710.356
 TG0.074-0.081-0.1540.5340.213-0.016-0.1990.093

BMD adjusted for disease duration, ESR, CRP, DAS28-ESR, RF, ACPA, β-CTX, ALP, IL-35, 25-(OH) VitD3, and medications. Abbreviations: BMD: bone mineral density; ESR: erythrocyte sedimentation rate; CRP: C-reaction protein; DAS28-ESR: disease activity score in 28 joints based on erythrocyte sedimentation rate; RF: rheumatoid factor; ACPA: anticyclic citrullinated peptide antibodies; BTMs: bone turnover markers; β-CTX: β-isomerised carboxy-terminal cross-linking telopeptide of type I collagen; ALP: alkaline phosphatase; IL: interleukin; HCQ: hydroxychloroquine; MTX: methotrexate; LEF: leflunomide; TG: tripterygium glycosides; OR: odds ratio; CI: confidence interval.